BriaCell Therapeutics Corp. (id:13686 BCT)
3.00 CAD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 8:38:22 PM)
Exchange closed, opens in 12 hours 51 minutes
About BriaCell Therapeutics Corp.
Market Capitalization 59.70M
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
| Headquarters (address) |
Bellevue Centre West Vancouver V7T 2X1 BC Canada |
| Phone | 604-921-1810 |
| Website | https://briacell.com |
| Employees | 16 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | BCT |
| Exchange | Toronto Stock Exchange |
| Currency | CAD |
| 52 week range | 3.00 - 8.00 |
| Market Capitalization | 59.70M |
| P/E forward | -2.83 |
| Beta | 1.82 |
| EPS | 3.00 |
| EPS Canada (ID:82, base:720) | 2.18 |